JP2006514950A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514950A5
JP2006514950A5 JP2004560831A JP2004560831A JP2006514950A5 JP 2006514950 A5 JP2006514950 A5 JP 2006514950A5 JP 2004560831 A JP2004560831 A JP 2004560831A JP 2004560831 A JP2004560831 A JP 2004560831A JP 2006514950 A5 JP2006514950 A5 JP 2006514950A5
Authority
JP
Japan
Prior art keywords
optionally
optionally substituted
aryl
ring
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004560831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514950A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/039619 external-priority patent/WO2004055010A2/en
Publication of JP2006514950A publication Critical patent/JP2006514950A/ja
Publication of JP2006514950A5 publication Critical patent/JP2006514950A5/ja
Pending legal-status Critical Current

Links

JP2004560831A 2002-12-13 2003-12-12 Ccr5拮抗薬としてのシクロプロピル化合物 Pending JP2006514950A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43362602P 2002-12-13 2002-12-13
PCT/US2003/039619 WO2004055010A2 (en) 2002-12-13 2003-12-12 Cyclopropyl compounds as ccr5 antagonists

Publications (2)

Publication Number Publication Date
JP2006514950A JP2006514950A (ja) 2006-05-18
JP2006514950A5 true JP2006514950A5 (https=) 2007-01-25

Family

ID=32595221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004560831A Pending JP2006514950A (ja) 2002-12-13 2003-12-12 Ccr5拮抗薬としてのシクロプロピル化合物

Country Status (8)

Country Link
US (1) US7569579B2 (https=)
EP (1) EP1569934B1 (https=)
JP (1) JP2006514950A (https=)
AT (1) ATE384724T1 (https=)
AU (1) AU2003296993A1 (https=)
DE (1) DE60318891T2 (https=)
ES (1) ES2298627T3 (https=)
WO (1) WO2004055010A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007614A1 (en) * 2003-07-03 2005-01-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 Monoamine oxidase inhibitors
RU2006125441A (ru) * 2003-12-15 2008-01-27 Джапан Тобакко Инк. (Jp) Производные циклопропана и их фармацевтическое применение
DK2195293T3 (da) 2007-08-22 2014-02-03 Astrazeneca Ab Cyclopropylamidderivater
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
DK2534149T3 (da) 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
BR112012020629A2 (pt) 2010-02-18 2018-06-19 Astrazeneca Ab forma cristalina, e, método para a terapia de um distúrbio
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
CA2796726C (en) 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ. アー. Lsd1阻害剤としての(ヘテロ)アリールシクロプロピルアミン化合物
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4077318B1 (en) 2019-12-18 2025-10-15 Ctxt Pty Ltd Benzimidazole dimers as modulators of sting
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69926806D1 (de) * 1998-12-18 2005-09-22 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
EP1392676B1 (en) * 2001-02-16 2006-12-13 Aventis Pharmaceuticals Inc. Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands

Similar Documents

Publication Publication Date Title
JP2006514950A5 (https=)
JP2006511555A5 (https=)
JP2006511552A5 (https=)
JP2006512339A5 (https=)
CN101969951B (zh) 化合物在制备治疗关节炎的药物中的方法
AU2014277506B2 (en) Bisulfate of Janus kinase (JAK) inhibitor and preparation method therefor
RU2006144709A (ru) Земещенные 2-хинолилоксазолы, пригодные в качестве ингибиторы фдэ4
WO2018057973A4 (en) Compounds and methods for ido and tdo modulation, and indications therefor
JP2011516428A5 (https=)
RU2002131887A (ru) Замещенные в орто-положении амиды антраниловой кислоты и их применение в качестве лекарственных средств
CN106573006A (zh) 作为药物的rip1激酶抑制剂杂环酰胺
RU2006105716A (ru) Производные пиридазина и их применение в качестве терапевтических средств
RU2015120216A (ru) Ингибиторы тирозинкиназы брутона
RU2015105262A (ru) Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах
JP2008526761A5 (https=)
JP2011506412A5 (https=)
RU2006130684A (ru) Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
RU2016150326A (ru) Производные изоиндолина для применения в лечении вирусной инфекции
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2002535401A5 (https=)
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
RU2001119054A (ru) Калиевая соль (S)-омепразола
RU2011117927A (ru) Карбаматное соединение или его соль
RU99112569A (ru) Бициклические арильные карбоксамиды и их терапевтическое применение
WO2019173613A1 (en) Substituted fused pyrrolo-diazepinones and uses thereof